Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease

This is the authors' abstract. We don't add key points for this paper.

This consensus on multiple myeloma-related bone diseases (MBDs) underscores the importance of a multidisciplinary approach that encompasses hematology, radiology, orthopedics, and additional specialties to tackle its intricate challenges. MBD, a prevalent and debilitating complication of multiple myeloma, leads to bone pain, fractures, and skeletal-related events (SREs), which profoundly impact patients’ quality of life. The guidelines offer a thorough framework for diagnosis, treatment, and continual assessment, emphasizing early detection and consistent monitoring using imaging techniques such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI). Treatment strategies prioritize the careful application of anti-myeloma agents, bisphosphonates, and denosumab to minimize bone loss and decrease SRE risk, complemented by surgical and radiotherapy interventions for structural or pain-related issues. Supportive care measures, including pain management, rehabilitation, nutritional support, and dental evaluations, play a crucial role in enhancing patient outcomes and preserving quality of life. This consensus advocates a standardized, evidence-based approach to managing MBD, ensuring comprehensive and coordinated care for patients. • A multidisciplinary approach is essential for managing multiple myeloma-related bone disease (MBD). • MBD in myeloma causes pain, fractures, and skeletal-related events (SREs), lowering patients' quality of life. • Guidelines stress early detection and monitoring via positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI). • Treatments focus on anti-myeloma agents, bisphosphonates, and denosumab. • Supportive care, including pain control and rehab, improves patient outcomes.